United States · FDA National Drug Code directory
POMBILITI ATGA
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 71904-200_5d85b45c-1ab9-41f2-b917-2e62606fb132
- Product NDC
- 71904-200
- Form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Composition / generic term
- cipaglucosidase alfa-atga
- Labeler
- AMICUS THERAPEUTICS US, LLC
- Marketing category
- BLA
- Marketing start / end (source format)
- 20231011
- Source listing expiry
- 20271231
Source-listed ingredients
- CIPAGLUCOSIDASE ALFA — 105 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, GLASS in 1 CARTON (71904-200-01) / 105 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS · 71904-200-01
- 10 VIAL, GLASS in 1 CARTON (71904-200-02) / 105 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS · 71904-200-02
- 25 VIAL, GLASS in 1 CARTON (71904-200-03) / 105 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, GLASS · 71904-200-03
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →